Aurora Spine saw revenues grow 10% year over year in the first quarter of 2025, according to financial results posted May 22.
The company reported $4.42 million in revenue during the first quarter, largely due to more ASC and pain center volume. Highlights of the first quarter include FDA clearance for the Aero facet fusion system, increased spine sales and completed data collection in the Refine study for the Zip interspinous fixation device.
Gross margins were 58% compared to 61.9% in the same period last year. The decrease in margins was due to increased shipping costs and higher distributor commissions. The company reported $3.9 million in operating expenses.
“Our prospects for the future are extremely positive, as there are several catalysts in place for the Company to grow revenues in fiscal 2025 by at least 20%,” CEO Trent Northcutt, said in the release. “We feel confident in our future growth given the immense R&D push we committed to in the past few years. Our confidence for the remainder of 2025 and beyond also stems from the launch of two products later this year, with the DEXA-L, a specialized lumbar interbody fusion device designed to match a patient’s bone density, to promote bone in-growth, and improve fusion rates in ALIF and LLIF procedures and our newest product platform AERO, a facet fusion system.”
